Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
复制标题
DOI：
10.1093/cid/ciy585
复制
发表时间：
2018-11-15
影响因子：
11.8
通讯作者：
Workowski, Kimberly A.
中科院分区：
文献类型：
--
作者：
Chung, Raymond T.;Ghany, Marc G.;Workowski, Kimberly A.
认识到及时指导快速发展的丙型肝炎管理领域的重要性，美国肝病研究协会（AASLD）和美国传染病学会（IDSA）开发了一个基于网络的流程，以快速制定和传播基于证据的建议。丙型肝炎病毒（HCV）指南网站于2014年启动，根据新的治疗药物和/或研究数据的需要定期更新。2017年9月以电子方式发布了重大更新，主要是由于批准了新的直接作用抗病毒药物和扩大了指南的范围。本次更新总结了最新发布的HCV指南，重点介绍了自2015年9月之前的印刷出版物以来新的或修订的建议。本文的建议是由代表AASLD和IDSA的志愿肝病学和传染病专家制定的，并经过了各自协会管理委员会的同行评审和批准。
Recognizing the importance of timely guidance regarding the rapidly evolving field of hepatitis C management, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) developed a web-based process for the expeditious formulation and dissemination of evidence-based recommenda-tions. Launched in 2014, the hepatitis C virus (HCV) guidance website undergoes periodic updates as necessitated by availability of new therapeutic agents and/or research data. A major update was released electronically in September 2017, prompted primarily by approval of new direct-acting antiviral agents and expansion of the guidance's scope. This update summarizes the latest release of the HCV guidance and focuses on new or amended recommendations since the previous September 2015 print publication. The recommendations herein were developed by volunteer hepatology and infectious disease experts representing AASLD and IDSA and have been peer reviewed and approved by each society's governing board.